|
Diamond Biofund Inc. is a biotechnology venture capital firm that invests in life sciences and medical innovation. The company focuses on new drug development, advanced medical devices, medical services, medical distribution channels, and agricultural biotechnology. It provides portfolio companies with support in corporate governance, technical research, clinical execution, commercial development, and capital market integration. Diamond Biofund Inc. was founded with founding shareholders including China Biotech, Fubon Financial Holding, Taishin Financial Holding, and Ruentai Group. The company operates through subsidiaries Diamond No.1 Investment Co., Ltd. and Diamond High-Tech Investment Co., Ltd. It targets globally competitive investment targets to accelerate value realization for its shareholders. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Asset Management | Homepage diamondbiofund.com |
| Sector Financial Services | IR page diamondbiofund.com/investor-relations/corporate-governance/boss | |
|
Tags
venture capital, biotechnology, life sciences, medical devices, new drug development, agricultural biotechnology, clinical execution, corporate governance, Diamond No.1 Investment Co. Ltd., Diamond High-Tech Investment Co. Ltd.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 10.973B |
| Market cap (USD) | $ 333.06M |
| P/E | 4.48 |
| PEG | — |
| P/BV | 0.94 |
| P/S | 4.28 |
| P/OCF | 9.63 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -12.0% |
| ROI | -12.7% |
| ROIC | -10.0% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -14.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | -1.073B | -2.229B | -2.44B | 1.016B | 3.064B |
| Net profit | -1.175B | -2.518B | -2.583B | 797.781M | 2.852B |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Share price | 16.5 | 32.7 | 48.8 | — | — |
| Price performance 12m | -0.5 | -0.33 | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Diamond Biofund Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.01% | 23,000 | $ 9,802.83 | Nov 16, 2026 |